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Abstract
Royal jelly (RJ) excreted by honeybees and used as a nutritional and medicinal agent has estrogen-like effects, yet the
compounds mediating these effects remain unidentified. The possible effects of three RJ fatty acids (FAs) (10-hydroxy-2-
decenoic-10H2DA, 3,10-dihydroxydecanoic-3,10DDA, sebacic acid-SA) on estrogen signaling was investigated in various
cellular systems. In MCF-7 cells, FAs, in absence of estradiol (E2), modulated the estrogen receptor (ER) recruitment to the
pS2 promoter and pS2 mRNA levels via only ERb but not ERa, while in presence of E2 FAs modulated both ERb and ERa.
Moreover, in presence of FAs, the E2-induced recruitment of the EAB1 co-activator peptide to ERa is masked and the E2-
induced estrogen response element (ERE)-mediated transactivation is inhibited. In HeLa cells, in absence of E2, FAs inhibited
the ERE-mediated transactivation by ERb but not ERa, while in presence of E2, FAs inhibited ERE-activity by both ERb and
ERa. Molecular modeling revealed favorable binding of FAs to ERa at the co-activator-binding site, while binding assays
showed that FAs did not bind to the ligand-binding pocket of ERa or ERb. In KS483 osteoblasts, FAs, like E2, induced
mineralization via an ER-dependent way. Our data propose a possible molecular mechanism for the estrogenic activities of
RJ’s components which, although structurally entirely different from E2, mediate estrogen signaling, at least in part, by
modulating the recruitment of ERa,E R b and co-activators to target genes.
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Introduction
Royal jelly (RJ), a yellowish material excreted by the
mandibular and hypopharyngeal glands of worker bees of the
genus Apis mellifera, is a food essential for the longevity of the queen
bee. RJ exerts estrogen effects in vitro and in vivo, similar to those
evoked by 17b-estradiol (E2) [1,2,3]. However, the mediators of
RJ’s estrogenic effects remain unknown. While RJ contains a
considerable amount of proteins, free amino acids, sugars,
vitamins and sterols, the medium chain fatty acids (FAs) 10-
hydroxy-2-decenoic (10H2DA), 3,10-dihydroxydecanoic (3,10
DDA) and sebacic (SA) acids (Fig. 1) are major and unique RJ
components [4,5,6].
Estrogens play pivotal roles in regulating the function of many
tissues and organs and estrogen signaling has been associated with
a number of diseases, including breast and uterine cancers,
disorders of lipid metabolism, cardiovascular diseases, autoim-
mune inflammatory diseases, osteoporosis, menstrual abnormali-
ties and infertility [7]. Estrogens exert their effects via intracellular
receptors, estrogen receptors alpha (ERa) and beta (ERb) [8,9,10].
In the presence of ligands, both ERa and ERb are activated and as
dimers interact with specific DNA sequences. Activated ERs
interact with other nuclear proteins, such as steroid receptor co-
regulators, altering the transcription rates of responsive genes. The
activated ERa and ERb can also bind to other transcription
factors, such as activator protein 1 (AP-1) and nuclear factor kappa
B (NF-kB), affecting their binding to their cognate DNA sequences
and their transcriptional effects [11]. More recently, the G protein-
coupled receptor, GPR30/GPER, has been shown to mediate
rapid estrogen effects as well as to regulate transcriptional
activation. Possible synergism and antagonism with classical
estrogen receptors has been suggested [12].
In the present study, we investigated the possible estrogenic/
antiestrogenic effects of the RJ-derived fatty acids, 10H2DA,
3,10DDA and SA, in various cellular systems in vitro. We
examined the ability of FAs, at physiologically achievable levels, to
modulate 1) the recruitment of ERa and ERb to the E2 responsive
region of the pS2 promoter in the MCF-7 cell line, 2) the
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activity of ERa and ERb on an ERE-driven Luc-reporter gene in
MCF-7 and HeLa cells and 4) the E2-induced recruitment of the
EAB1 co-activator peptide to ERa. Furthermore, we examined
the potential of FAs to induce mineralization in KS483 osteoblasts,
which is an ER regulated process in bone remodeling. Finally, we
assessed the capacity of FAs to bind to ERs and we also modeled
the interaction of FAs with ERa to reveal potentional sites of
interaction.
Materials and Methods
1. Isolation and identification of fatty acids
The 10-hydroxydec-2-enoic (10H2DA), 3,10-dihydroxydeca-
noic (3,10DDA) and sebacic (SA) fatty acids were isolated from RJ
by chromatographic separation (Liquid Chromatography, LC and
Medium Pressure Liquid Chromatography, MPLC) and identified
by means of spectroscopic data analysis, mainly via the concerted
application of 1D and 2D Nuclear Magnetic Resonance (NMR)
techniques (Heteronuclear Multiple Quantum Coherence,
HMQC and Heteronuclear Multiple Bond Coherence, HMBC)
and mass spectrometry, as described previously [6].
2. Cell cultures
A cervical adenocarcinoma ER negative cell line (HeLa, ATCC
Cell Bank), an endometrial ER positive cancer cell line (Ishikawa
ECACC Cell Bank, No 99040201), an ERa positive breast
carcinoma cell line (MCF-7, ATCC Cell Bank) and a human
hepatoma ER negative cell line (Huh7, ATCC Cell Bank) were
used. For chromatin immunoprecipitation (ChIP) experiments, a
stable cell line, MCF-7 tet-off Flag-ERb that expresses an
inducible version of ERb fused to a Flag-tag, was used. This cell
line expresses endogenous ERa. The KS483 bone cell line is a
non-transformed stable subclone of a parental mouse cell line KS4
that has the ability to form mineralized nodules in vitro. All cell
lines were maintained as previously described [13,14,15].
3. Chromatin immunoprecipitation assay (ChIP)
Cells were seeded in 150-mm dishes and grown in the presence
(ERa+/ERb2) or in the absence of tetracycline (ERa+/ERb+) for
4 days in phenol red (PR) free DMEM supplemented with 10%
dextran-coated charcoal (DCC)-treated fetal bovine serum (FBS).
Cells were treated with 10
28 ME 2 or 10
26 M FAs for 45 min.
Co-incubation was performed with 10
28 ME 2 and 10
26 M FAs.
ChIP was performed as previously described [14,16]. The anti-
ERb rabbit polyclonal antibody LBD [17] was used to perform
ChIP for ERb and the rabbit polyclonal anti-ERa antibody HC-
20 was used for ERa ChIP. Normal rabbit IgG was used for
determination of non-specific binding. The final ChIP DNA was
amplified by real-time PCR with SYBR green master mix RT-
PCR reagent, using primers that amplify the ER binding region
from the pS2 promoter. 18s was used as negative control. The
primer pairs are listed in Table 1.
4. Determination of mRNA and protein levels
Cells were seeded in 6-well plates and grown in the presence
(ERa+/ERb2) or in the absence of tetracycline (ERa+/ERb+) for
4 days in PR free DMEM 10% DCC-FBS. Cells were treated with
10
28 ME 2 or 10
210–10
25 M FAs for 24 hrs. Co-incubation was
performed with 10
28 ME 2 and 10
29,1 0
27 or 10
26 M FAs. Total
RNA were purified using the RNeasy Mini Kit. Two mg of total
RNA was reverse transcribed into cDNA using TaqMan Reverse
Transcription Reagents with random hexamer primers. Real time
PCR assays were conducted using SYBR green master mix RT-
PCR reagent. Acidic ribosomal phosphoprotein PO (36B4) was
used as an internal control gene [18]. The sequences of the
primers are listed in Table 1. For detecting ERa protein levels,
cells were incubated as mention above. Western blot analysis was
carried out as previously described [19] using the following
antibodies: anti-ERa (HC-20, Santa Cruz Biotechnology) and
anti-b actin (A2228, Sigma).
5. Transfection studies in HeLa cells and MCF-7 cells
Before each transfection experiment cells were maintained for 2
days in PR free DMEM containing 10% DCC-FBS. For
transfection assays, cells were plated in 6-well or 24-well plates
in PR free DMEM with 10% DCC-treated FBS and transfected
using reagents and plasmids as stated in Table 2, according to the
manufacturer’s instructions and as previously described [13].
MCF-7 cells transfected with EREs were incubated with E2
(10
28 M) or FAs (10H2DA, 3,10DDA, SA) in a concentration
range of 10
210–10
25 M. Co-incubation of FAs with E2 (10
28 M)
was also carried out. MCF-7 cells transfected with Glucocorticoid
Figure 1. Structures of 17b-estradiol (17b-E2), 10-hydroxy-2-decenoic acid (10H2DA), 3,10-dihydroxydecanoic acid (3,10DDA) and
sebacic acid (SA).
doi:10.1371/journal.pone.0015594.g001
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(DEX) (10
26 M), RU486(10
26 M) or FAs (10H2DA, 3,10DDA,
SA) in a concentration range of 10
210–10
25 M. Co-incubation of
FAs (10
27 M) with DEX (10
26 M) was also performed. HeLa cells
transfected with ERa or ERb were incubated with E2 (10
29 M) or
ICI182780 (10
28) or 4OH-tamoxifen (4OH-TMX) (10
28 M) or
FAs (10H2DA, 3,10DDA, SA) in a concentration range of 10
210–
10
25 M. Co-incubation of E2 (10
29 M) with ICI182780 (10
28 M)
or FAs (10
27–10
26 M) was also conducted. Cells were harvested
24 hrs later and cell extracts were assayed for luciferase, b-
galactosidase and renilla luciferases, as stated in Table 2.
6. Mammalian two-hybrid assay
The day before the transfection, Huh7 cells were seeded into
24-well plates in PR free medium 10% DCC-FBS and 2 mM L-
glutamine. Cells were transfected with Genejuice as instructed by
the manufacturer. After transfection, cells were treated with E2
(1 mM), 4OH-TMX (500 nM), FAs (5 mM) or FAs in combination
with E2 for 16 h. C. Luciferase and b-galactosidase activity was
assayed as earlier described [15].
7. Mineralization assay in KS483
For the assays, cells were seeded in 12-well plates in a-MEM
10% DCC-FBS. Three days after plating, cells reached confluence
and were subsequently induced to differentiate by the addition to
the culture medium of 50 mg/ml ascorbic acid in the absence or
presence of FAs in a concentration range 10
210–10
27 M. E2
(10
29–10
26 M) was used as positive control. Co-incubation with
ICI182780 (10
27 M) was also performed. B-glycerophosphate was
added after day 10. The medium with the reagents was refreshed
every 3–4 days for 24 days in total. After 24 days, cells were rinsed
with PBS. The number of mineralized bone nodules was identified
with Alizarin Red-S. For Alizarin Red- S (sodium alizarin
sulphonate) staining, 2% Alizarin Red- S (Sigma) was prepared
in distilled water and the pH was adjusted to 5.5. Cultures were
fixed with 5% formalin (10 min), washed, and stained with
Alizarin Red- S for 5 min. After removal of unincorporated excess
dye with distilled water, the mineralized nodules were labeled as
red spots. Mineralized nodules were counted by light microscopy
at a 10-fold magnification as described previously [13,20].
8. MTT cell viability assay
Ishikawa cells and MCF-7 were cultured and the effect of FAs
(1.6610
27–4610
24 M) on cell viability was estimated by a
modification of the MTT assay, as previously described [13].
This assay measures the fraction of active mitochondria of living
cells. Thus, since results depend both on the mitochondria activity
per cell and on the number of cells present, MTT assay estimates
cell proliferation and survival [21].
9. Ligand binding assay
The ligand binding domain of the human ERa (hERa-LBD)
and human ERb (hERb-LBD) were produced individually in
Escherichia coli in 2xLB medium supplemented with 50 mM biotin.
The cells were harvested by centrifugation and the cell pellet
stored frozen at 220uC. The pellets were suspended in Tris buffer
and the cell walls were disrupted in a Microfluidizer M-110L. The
supernatants with receptor were stored at 270uC. The expression
of recombinant ERa and ERb, respectively, in the extracts was
confirmed using the ERa selective agonist PPT (propylpyrazol
Table 1. Primer pairs for amplification of ChIP enriched regions of pS2 promoter and 18s and mRNA levels of ERa, pS2 and acidic
ribosomal phosphoprotein PO (36B4).
Forward Reverse
ChIP 18S GCTTAATTTGACTCAACACGGGA AGCTATCAATCTGTCAATCCTGTC
pS2 CCT CCC GCC AGG GTA AAT AC CCG GCC ATC TCT CAC TAT GAA
mRNA ERa GAA TCT GCC AAG GAG ACT CGC ACT GGT TGG TGG CTG GAC AC
pS2 CATCGACGTCCCTCCAGAAGAG CTCTGGGACTAATCACCGTGCTG
36B4 GTG TTC GAC AAT GGC AGC AT GAC ACC CTC CAG GAA GCG A
doi:10.1371/journal.pone.0015594.t001
Table 2. Transfection conditions used in HeLa and MCF7 cells. Plasmids and reagents are listed accordingly.
Plasmids DNA quantity/well Reagents
MCF7-ERE ERE (2xERE-TATA-Luc) 0.2 mg Lippofectamine (Invitrogen)
pRL-TK (Renilla-Promega) 0.01 mg
MCF7-GRE GRE (MMTV-Luc) 0.2 mg Effectene Tranfection Reagent (Qiagen)
b-gal (pCMVb) 0.2 mg
HeLa-ERa ERa (HO-hERa) 0.5 mg Polyfect Transfection Reagent (Qiagen)
ERE (3xERE-TATA-Luc) 0.5 mg
b-gal (pCMVb-Clontech) 0.5 mg
HeLa-ERb ERb (pSG5-hERa) 0.5 mg Polyfect Transfection Reagent (Qiagen)
ERE (3xERE-TATA-Luc) 0.5 mg
b-gal (pCMVb-Clontech) 0.5 mg
doi:10.1371/journal.pone.0015594.t002
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nyl) propionitrile) [22,23]. Receptor extracts were thawed on ice
from 270uC and mixed with streptavidin coated SPA beads in
pH8 buffer (1 mM EDTA, 18 mMK2HPO4, 2 mM KH2PO4,
20 mM Na2MoO4, 1 mM TCEP). The compounds were diluted
in DMSO to 12 concentrations and 18 ml of each dilution was
added in duplicates to a Corning 3706 plate. The final assay
concentration of tracer was 1.2+/20.08 nM and the compound
concentrations ranged from 37 pM to 157 mM in a total volume of
88 ml. The plates were incubated on a shaker overnight at room
temperature, centrifuged (2000 rpm, 5 min) and measured with
top and bottom detectors on 12 detector Trilux Microbeta. A four
parameter logistic fit (4PL) was used to analyze the data with XLfit
software from IDBS in Microsoft Excel.
10. Modeling of fatty acid interactions with ERa
Three-dimensional models of the FAs (10H2DA, 3,10 DDA,
and SA), as well as of the co-factor peptide EAB1, were built using
PyMol. The FAs were docked to the ligand pocket and to the co-
activator binding site and then the complexes were minimized
using 100 steps of Steepest Descent followed by 500 steps of
Adopted Basis Newton-Raphson minimization in CHARMM
[24]. The parameters for the FAs were compiled using the
CHARMM force field for proteins [25], lipids [26,27] and the
CHARMM general force field [28]. The X-ray structure of the
ERa receptor with PDB entry code 1GWR [29,30] was used in
the calculations. Missing atoms were built and E2 was parame-
terized as previously described [31]. The binding of the organic
molecules to the receptor was evaluated on the basis of the
interaction energy (Coulomb and van der Waals interactions)
between receptor and ligand or cofactor peptide.
Results
The RJ’s FAs may modulate estrogen signaling by various
mechanisms, involving binding to the ligand binding pocket of the
receptor, influencing the abundance/distribution of ER subtypes
and their recruitment to E2 responsive genes, modulating co-
activators and/or co-repressors, physically blocking co-activator
and co-repressor recruitment, or alternatively by inducing proteins
which may disrupt ER dimerization. Estrogenic effects of RJ FAs
could also involve GPR30-mediated signaling [12]. We investigated
the RJ FAs with regard to effects on a panel of in vitro bioassays that
detect estrogenicity/antiestrogenicity of a test substance [21,32].
We examined the estrogenic/antiestrogenic activity of 10H2DA,
3,10DDAandSA,whichwereisolatedandidentified previously[6],
in several estrogen-responsive biological systems (Fig. 1). E2 was
used as positive control for agonist activity, whereas ICI182780, a
well-known complete estrogen antagonist, served as control for
antagonist action. 4OH-TMX served as control for partial estrogen
agonism/antagonism activity.
FAs induce ERb recruitment to the pS2 promoter
Figure 2.I. shows the effects of FAs on ERa (A) and ERb (B)
recruitment to the pS2 gene promoter. FAs did not induce ERa
recruitment to the pS2 promoter (Fig. 2.I.A). As expected, E2
(10
28 M) enhanced recruitment of ERa to the pS2 promoter
(Fig. 2.I.A). However, co-incubation of either FA (10
26 M) with E2
(10
28 M) inhibited E2-dependent recruitment of ERa to the pS2
promoter. Fig. 2.I.B shows that all FAs and E2 (10
28 M) increase
recruitment of ERb to the pS2 promoter. However, upon co-
incubation of either FAs at 10
26 M with E2 (10
28 M), decreased
recruitment compared to that observed for E2 alone is observed for
ERb to the pS2 promoter (p,0.01–0.001).
FAs modulate pS2 mRNA levels
In the presence of ERa, FAs at all concentrations tested did not
change pS2 mRNA levels, while pS2 mRNA levels were increased
after E2 treatment (Fig. 2.II.A). However, when co-incubated
(10
26 M) with E2, FAs decreased E2-mediated induction of pS2
mRNA consistent with the results of ChIP assay. When ERb was
co-expressed with endogenous ERa, 10H2DA and 3,10DDA
significantly decreased pS2 mRNA levels at concentrations of
10
26 M (Fig. 2.II.B). In this system, 10H2DA and 3,10DDA also
abolished the induction of pS2 mRNA by E2. In MCF-7 cells, with
or without ERb expression, FAs alone, at all concentrations tested,
do not affect ERa mRNA or nuclear ERa protein levels (Fig. S1).
FAs reduce ERE-mediated transcriptional activity in MCF7
cells
The addition of 10H2DA, 3,10DDA or SA (10
210–10
25 M), in
the presence of E2 (10
28 M), inhibited the E2-mediated induction
of an ERE-driven luciferase reporter gene in MCF-7 cells in a
dose-dependent manner (Fig. 3.II). When incubated in the absence
of E2, all FAs increased slightly, but not significantly, the basal
ERE-driven luciferase activity, in the concentration range of
10
26–10
25 M (Fig. S2). In MCF-7 cells transfected with GRE-
driven luciferase reporter, the addition of 10H2DA, 3,10DDA or
SA (10
210–10
25 M) did not alter the GRE-mediated transcrip-
tional activity, when assayed alone or in the presence of DEX
(10
26 M) (Fig. S3).
FAs modulate ERa- and ERb-mediated reporter gene
activity in HeLa cells
The ability of E2, ICI182780, 4OH-TMX and FAs to modulate
ERE-driven luciferase activity in HeLa cells transfected with either
ERa (A) or ERb (B) is shown in Figure 3.I. The presence of E2
(10
29 M) increased the ERa- and ERb-mediated luciferase
activity, while co-incubation with ICI182780, as expected,
diminished the E2-enhancing effect in both systems. ICI182780
(10
28 M), when added alone, diminished the basal luciferase
activity mediated by ERa and ERb. In agreement with previous
reports, 4OG-TMX was a weak agonist of ERa and a potent
antagonist of ERb in this system [33]. All FAs enhanced the ERa-
mediated activity, when incubated alone at various concentrations
(10
210–10
25 M) (Fig. S4). Moreover, FAs attenuated the effects of
E2 under co-incubation conditions (Fig. 3.I.A). All FAs diminished
ERb-mediated activity when incubated alone at various concen-
trations (10
210–10
25 M) (Fig. S4). These FAs also attenuated the
effects of E2 under co-incubation conditions (Fig. 3.I.B). Figure 3.I
shows the data for the effects of FAs on ERE-luciferase activity at a
FAs concentration of 10
26 M and co-incubation with 10
29 ME 2
(full data in Fig. S4).
FAs alter E2- induced co-activator recruitment to ERa
The molecular basis for ER agonism is dependent on formation
of a hydrophobic surface within the LBD, which represents the
docking surface for a-helical leucine-rich peptide motifs in co-
activators [29]. A mammalian two-hybrid assay was used to
monitor induction of an agonist conformation in the receptor,
which allows recruitment of a peptide containing an a-helical
leucine-rich motif (LxxLL) upon ligand binding [15]. The LxxLL-
containing peptide EAB1 is strongly associated with the receptor
when E2 is added, indicating a structural change where the
receptor adopts an agonist conformation. The fatty acids, while
alone, do not induce a detectable conformational change in ERa.
However, when the fatty acids are co-incubated with E2,
recruitment of the LxxLL peptide is diminished (Fig. 3.III).
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As shown in Fig. 4, the presence of E2 (10
29–10
28 M) induced
mineralization in osteoblasts, as expected [20]. Similarly,
10H2DA and SA at 10
29–10
28 M exhibited an agonistic effect
by inducing nodule formation, an effect which was diminished in
the presence of ICI182780, thereby suggesting an ER-mediated
action.
FAs do not bind to ERa or ERb
To examine a possible binding of FAs to the ligand pocket of the
receptor, we used a competition binding assay. Using ERa (PPT)
and ERb (DPN) selective agonists, we confirmed the expression
and specificity of the receptors in the cell extracts used in this
assay. PPT exhibited 1000-fold higher relative binding affinity in
ERa- than in ERb-expressing cell extracts (10
29 M and 10
26 M
respectively), while DPN had 200-fold higher relative binding
affinity in ERb-expressing cell extracts compared to ERa-
expressing cell extracts (10
28 M). E2 had equal Relative Binding
Affinity (RBA) in both cell extracts (10
29). The assays revealed that
SA and 3,10DDA did not bind to ERa or ERb at all
concentrations tested (data not shown). However, 10H2DA
exhibited binding to both receptors, but only at extreme
concentrations (10
24 M).
Modeling of FA interactions with ERa
The FAs were docked in the ERa ligand binding pocket, with
the EAB1 peptide present at the co-activator binding site, and
interaction energies between FAs and ERa were obtained in the
range of 244 to 263 kcal/mol. For comparison, the interaction
energy between the receptor molecule and E2 obtained by the
same computational procedure is -70 kcal/mol (Fig. 5). We also
docked SA at the co-activator binding site, replacing EAB1. In this
case also, the interaction energy between the two molecules was
favorable (about -140 kcal/mol). However, when SA was docked
at other locations on the protein surface, distant from the co-
activator binding site, the interaction energy turned out to be
similar or even more favorable (data not shown).
Discussion
In this study, we determined the possible estrogenic/antiestro-
genic properties of 10H2DA, 3,10DDA and SA, isolated from RJ
and identified by spectroscopic methods [6]. In choosing the
concentrations we considered 1) the commonly used RJ dietary
supplementation (1–3 g daily), 2) the concentration of 10H2DA
and the concentration of sebacic acid in RJ (3–6% and 0.5%
respectively) [34,35], 3) the concentration of 10H2DA, sebacic
Figure 2. Effects of FAs on ERa (A) and ERb (B) recruitment to the pS2 promoter (I). Effects of FAs on pS2 mRNA levels in the presence of
ERa (A) or ERa and ERb (B) together (II). MCF-7 tet-off Flag-ERb cells were treated as mentioned in Materials and Methods. Results are expressed as
fold binding compared to vehicle and normalized to recruitment of ERs to the 18S gene (I) and 36B4 (II). Treatment with 10
25 M of FAs gave similar
results (data not shown). Mean values 6 SD are shown from three independent experiments. *Significantly different from vehicle (*p,0.05, **p,0.01,
***p,0.001), +significantly different from E2 (10
28 M) ((+p,0.05, ++p,0.01, +++p,0.001).
doi:10.1371/journal.pone.0015594.g002
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samples in Greece (40–50%, 5%, 4% and 20% respectively), 4) the
human blood volume and bioavailability. Based on the above
information, we decided to examine the biological effects of FAs in
a concentration range of 10
210 M–10
25 M, which are physiolog-
ically achievable concentrations.
Using a ChIP assay in MCF-7 breast cancer cells, which are
stably transfected with an inducible version of ERb and express
endogenous ERa, we examined the ligand-dependent recruitment
of ERa and ERb to chromatin. None of the tested FAs could
modulate ERa recruitment to the pS2 promoter, whilst they
increased ERb recruitment to this promoter. All FAs inhibited the
effect of E2 on ERa and ERb recruitment. Consistent with the
effects on receptor recruitment to DNA, experiments revealed that
in the presence of ERb, FAs could decrease pS2 mRNA levels,
when added alone, and that they decreased E2’s effect in the
presence and absence of ERb. However, since in this cell system
endogenous ERa is always present, effects on pS2 expression
cannot easily be determined for ERb alone. We further assessed
the effects of FAs on ERa alone and ERb alone in HeLa cells. This
cell line, in contrast to MCF-7 cells, lacks endogenous ER. In
HeLa cells, we demonstrated that all FAs, when assayed alone,
were weak enhancers of ERa-mediated activity, while they
antagonized ERb-mediated effects. In the presence of E2 they
antagonized the E2-mediated effects via ERa and ERb. The well
characterized selective estrogen receptor modulator (SERM)
4OH-TMX also exhibited agonistic effects on ERa-mediated
activity, while it was a complete antagonist of ERb-mediated
action. This is in agreement with a previous study reporting that
4OH-TMX induced ERE-mediated reporter gene activity in a
stably transformed ERa expressing cell line, but exhibited pure
antagonism in the corresponding ERb expressing system [33].
Recruitment of co-factors is an essential component of ER
signaling. The best defined structure-function of a co-regulator
interaction is with co-activators that interact through a conserved
LxxLL motif, termed an NR box. Interestingly, in MCF-7 cells we
show that the recruitment of the EAB1 co-activator peptide upon
E2 binding is reduced when FAs are present. This suggests that
Figure 3. Effects of FAs on ERE-mediated transactivation in HeLa cells transfected with ERa (A) or ERb (B) (I). Effects of FAs, on ERE-
mediated transactivation in MCF-7cells (II). Cells were transfected under conditions as shown in Table 2 and treated as mentioned in Materials and
Methods. Results represent the mean 6 SD of three independent experiments. *Significantly different from vehicle (*p,0.05, **p,0.01, ***p,0.001),
+significantly different from E2 (10
28 M) (+p,0.05, ++p,0.01, +++p,0.001). Analysis of ER-co-activator peptide (EAB1) interaction with mammalian
two-hybrid assay (III). Huh7 cells were transiently transfected and treated as mentioned in Materials and Methods. Luciferase activity was normalized
to b-galactosidase activity. Mean values 6 SE are shown from the results of four independent experiments (* p,0.05 or p,0.01 significantly different
from E2 (10
26 M).
doi:10.1371/journal.pone.0015594.g003
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conformational response at the co-activator binding site, leading to
masking of the co-activator site.
In the ERE-driven luciferase reporter gene assay in MCF-7
cells, all 3 FAs inhibited the E2-mediated increase in luciferase
activity, suggesting an ER-mediated effect and a common signal
transduction pathway for E2 and FAs at the level of ERE-
containing promoters. Additionally, all 3 FAs showed a trend
towards increasing the ERE-driven luciferase activity when tested
alone. This is consistent with results from Suzuki et al. showing
that 10H2DA increased the ERE-driven luciferase activity in
MCF-7 cells at the same concentration range. However, co-
incubation of FAs with E2 was not investigated in their study [36].
In previous reports [2] fresh RJ displays agonistic activity in the
Figure 4. Effect of E2 and FAs on mineralization of KS483 cells. Cells were treated as mentioned in Materials and Methods. Results are
expressed as percentage of vehicle. Mean values 6 SD are shown from the results of three independent experiments. (* p,0.05 or **p,0.01 or
***p,0.001 significantly different from vehicle, + p,0.05 or ++p,0.01 significantly different from E2 (10
29 M) or FAs (10
29 M).
doi:10.1371/journal.pone.0015594.g004
Figure 5. Modeling of interactions of fatty acids with ERa. A. The fatty acid 10H2DA in the ligand pocket of ERa. The protein molecule is
represented by its contact surface, whereas the fatty acid is represented by spheres (oxygen atoms in red, carbon atoms in grey). B. The pair Glu353-
Arg394 (residue numeration follows that of PDB entry 1GWR) and the carboxyl group of 10H2DA (van der Waals spheres) in the ligand pocket of the
estrogen receptor. The orientation of the protein molecule is identical to that in A. The co-activator EAB1 is represented by ribbon in blue.
doi:10.1371/journal.pone.0015594.g005
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to that observed for E2 whereas the isolated FAs in our study show
little agonist activity and possess antagonistic activity. RJ contains
multiple FA components [6] and data indicate that 10H2DA,
sebacic acid and 3,10 DDA (investigated in this study) may not be
the only FA determinants that predict estrogen/antiestrogen
activity in RJ [36]. Additionally, RJ may exhibit biological effects
determined by synergistic and/or antagonistic interactions be-
tween its constituents thus showing different biological effects than
the biological activity of its isolated components.
The specificity of FAs with regard to steroid receptor activation
was explored by assaying the effects of FAs in MCF-7 cells on
GRE-mediated transactivation. The FAs did not alter the basal
nor the Dex-induced GRE-mediated transcriptional activity,
indicating that the inhibition by FAs has specificity with respect
to modulation of NR-mediated functions. In line with our findings,
Thurmond et al. [37] proposed that medium chain FAs
(hexanoate) at high concentrations (mM range) interacted with
ERs to inhibit ligand stimulated transcription, while there was no
effect on GR-mediated activity. Previous reports have shown that
short chain FAs (valproic acid or butyrate and methoxyacetic acid)
may act as deacetylase inhibitors at high concentrations (mM
range) resulting in the induction of transcriptional silencing of ERa
expression, which would imply that they are antiestrogenic in
MCF-7 cells [38,39,40,41]. The antiestrogen effects of the above
short chain FAs are considered an effect that may be due to their
inherent HDAC inhibitory activities, since they have all been
shown to reduce endogenous ERa expression and have been
characterized as HDAC inhibitors. Interestingly, a recent report
showed that methoxyacetic acid (MAA at mM concentrations)
modulates ERa and ERb-mediated signaling, lowers endogenous
ERa expression and antagonizes E2-stimulated expression of ERa
target genes, yet it does not compete with E2 for binding to ERa
[41,42]. However, in our study, FAs (at mM concentrations) did
not affect ERa mRNA or protein levels.
We have explored possible mechanism(s) for the effects of FAs on
ER signaling by molecular modeling. As mentioned above, it is
possible that the FAs compete with the LXXLL- containing co-
activator for the activation function domain 2 (AF2) binding site of
the receptor. Of note, docking experiments showed significant
favorable interaction energy between the FAs and ERs. However,
similar interaction energies were also observed for other locations on
the protein’s surface, distant from the co-activator binding site.
Among the locations showing substantially more favorable intermo-
lecular interactions (2211 kcal/mol) is a region including the loop
around Tyr459. This loop is part of the subunit interface in the
dimeric ER. Hence, binding of FAs may interfere with the dimeriza-
tion of ERs and in this way influence co-activator binding (Fig.5).
FAs may bind to the ligand pocket, thus competing with E2. The
computational fitting showed very good compatibility of the ligand
pocket for all three FAs (Fig.5). Although the calculated interaction
energies between ligands and receptor are only indirectly related to
bindingaffinities,theydoindicatethat,similarlytoE2,thethreeFAs
interact favorably with the ER when they are in the ligand pocket.
However, our competition binding study did not show any binding
of SA and 3,10DDA and binding only at extreme concentrations
(10
24 M) of 10H2DA, indicating that an interaction with ERs is not
mediated via the ligand binding pocket. In agreement, Suzuki et al
Figure 6. Flow chart of assays and summary of findings. Conclusions are highlighted in lined text boxes (I). Possible molecular mechanism for
how FAs modulate E2 signaling through ERs (II). A. Classical E2 regulation of gene transcription through recruitment of ERa or ERb to the promoter region
B.InthepresenceofE2,FAsseemtoblock theeffectofE2onERa andERbrecruitmenttoDNAandgeneexpression(pS2andERE-Luc).FAs couldbindtoa
distinct region away from ligand binding pocket either to the co-activator binding pocket or to the dimerization region. This is consistent with the lack of
competition by FAs for E2 binding to the ligand binding pocket and with the interference of FAs with E2 induced binding of a co-activator peptide.
doi:10.1371/journal.pone.0015594.g006
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upon the ability of E2 to bind to ERa and 50% inhibition of E2 to
bind to ERb at a concentration of approximately 100 mM [36].
In line with our findings, a recent study on 3,39-diindolyl-
methane, a selective activator of ERb that does not bind to ERb,
proposes a possible mechanism of activation through recruitment
of co-activators (i.e. SRC-2) [43]. Moreover, it has been shown
that the methoxyacetic study which modulates ERa signaling yet
does not bind to ERa [41]. Of note, recent findings indicate that
ligands, without binding affinity to ERa, activate GPR30 signaling
and may act synergistically or may antagonize ERa-mediated gene
expression [12]. Future studies should address the potential of FAs
to activate GPR30 signaling or phosphorylation pathways in
cooperation with ERs.
On the basis of the findings by Narita et al. [3] demonstrating that
RJ stimulates bone formation, we used the osteoblastic cell line
KS483 followed by the Alizarin Red-S staining as a model system to
study the effect of FAs on the mineralization process [20], which is
k n o w nt ob ea ne s t r o g e ni n d u c e de f f e c t .T h em u r i n eK S 4 8 3c e l ll i n e
is a mesenchymal precursor cell line, which differentiates into mature
mineralizing osteoblasts during a three-week culture period, when
cultured under osteogenesis inducing conditions. This differentiation
process can be divided in a proliferation, matrix formation, matrix
maturation and finally a mineralization phase, according to the
model of Stein and Lian [44,45]. Thus, the defining characteristic of
the mature osteoblast is its ability to produce a mineralized bone
matrix. Moreover, KS483 cell model is among few osteoblastic
culture systems that can produce discrete, three-dimensionally
organized mineralized matrices which are recognizably bone like.
These bone nodules consist of woven bone matrix covered by
cuboidal osteoblastic cells and containing osteocyte-like cells
embedded in the matrix. Characterization of mineralized bone
nodules has demonstrated that the processes of nodule formation,
matrix deposition and subsequent mineralization follow a well
ordered, temporallydefined pattern which appearsanalogoustobone
formation and mineralization in vivo. Low concentrations of SA or
10H2DA significantly induced mineralization, which was suppressed
by the addition of ICI182780, indicating an ER-mediated effect. As
expected, the presence of E2 significantly stimulated the mineraliza-
tion of osteoblasts [20]. Our results imply that 10H2DA and SA may
be the RJ components that stimulate osteoblasts. None of the FAs
stimulated or inhibited cell viability/proliferation of endometrial
cancer (Ishikawa) or breast cancer (MFC-7) cells (Fig. S5). The
antiestrogeniceffectofFAsinbreastcancercells,theirfavorableeffect
on osteoblasts and the lack of effect on endometrial cell viability
suggest that FAs may be potential natural SERMs.
RJ is used extensively in commercial nutritional supplements,
medical products, and cosmetics in many countries, while SA, one of
its major components, is widely employed in medical practice, e.g.
parenteral nutrition, orthopedic applications, drug delivery systems,
vaccine development [46,47,48,49,50]. This honey bee-excreted
biological fluid possesses estrogen-like activity, yet the compounds
mediating its estrogenic effects are largely unknown. The present
report investigated the effects of RJ-derived FAs, namely 10-
hydroxy-2-decenoic, 3,10-dihydroxydecanoic and sebacic acid, on
estrogen signaling (Fig.6.I.) and suggests that these RJ-derived
medium chain fatty acids, structurally entirely different from E2,
mediate estrogen signaling, at least in part, by modulating the
recruitmentof ERa,ER b andcoactivatorstotarget genes(Fig.6.II.).
Supporting Information
Figure S1 Effects of FAs on ERa mRNA and nuclear ERa
protein levels in the presence of ERa or ERa and ERb
together. A–B. MCF-7 tet-off Flag-ERb cells were treated for
24 hrs with E2 (10
28 M) or FAs (10H2DA, 3,10DDA, SA) (10
210–
10
25 M). Results are expressed as induction compared to vehicle
and normalized to 36B4 mRNA levels. Mean values 6 SD are
shown from three independent experiments. C–D. MCF-7 tet-off
Flag-ERb cells were treated with vehicle or FAs (10H2DA,
3,10DDA, SA) (10
25–10
26 M). Cells were harvested 24 hrs later,
nuclear extract prepared and ERa detected by Western blotting.
b-Actin was used as loading control.
(TIF)
Figure S2 Effects of FAs on ERE mediated transactiva-
tion in MCF-7 cells. MCF-7 cells were transfected under
conditions as shown in Table 2 and treated with FAs (10H2DA,
3,10DDA, SA) (10
210–10
25 M) alone. Results are normalized to
renilla activity and expressed as percentage of luciferase activity in
E2 incubated samples. Results represent the mean 6 SD of 3
independent experiments.
(TIF)
Figure S3 Effect of DEX, FAs on luciferase activity in
MCF-7 cells transfected with a GRE-driven promoter.
MCF-7 cells were transfected under conditions as shown in Table 2
and treated with FAs (10H2DA, 3,10DDA, SA) (10
210–10
25 M)
alone or with the presence of DEX (10
29 M). Results of luciferase
activity are expressed as percentage of vehicle and normalized to
b-galactosidase activity. Columns and bars represent mean value
6 SD of the results of three independent experiments.
(TIF)
Figure S4 Effects of FAs on ERE mediated transactiva-
tion in HeLa cells transfected with ERa or ERb. HeLa cells
were transfected under conditions as shown in Table 2 and treated
with E2 (10
29 M), ICI182780 (10
28 M), 4OH-TMX (10
28 M) or
FAs (10H2DA, 3,10DDA, SA) (10
210–10
25 M). Co-incubation of
ICI 182780 (10
28 M) with E2 (10
29 M) was also done. Results are
expressed as percentage of vehicle and normalized to the b-
galactosidase activity.Meanvalues6 SDareshown from theresults
of three independent experiments. All FAs induced significantly the
ERa-mediated Luc activity (significance ranging from p,0.05 to
p,0.001), whereas they diminished ERb-mediated Luc activity
(significance ranging from p,0.01 to p,0.001).
(TIF)
Figure S5 Effect of FAs on cell viability. MCF-7 (A) and
Ishikawa (B) cells were incubated at a concentration range (0.16–
400 mM) for 48 hrs. Cell viability was determined by the MTT
assay. Each point of the dose response curve is the average of four
experiments. SD was less than 4% of the average value.
(TIF)
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